Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alligator Bioscience AB ( (SE:ATORX) ) has issued an update.
Alligator Bioscience announced it will host a virtual R&D Day on August 19, 2025, to provide an update on its R&D pipeline, focusing on its lead candidate, mitazalimab, which is preparing for Phase 3 development. The event will cover clinical data, biomarker findings, and ongoing trials, with implications for stakeholders as it precedes the TO 13 warrant exercise period in September 2025.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company specializing in the development of clinical-stage tumor-directed antibody drugs, primarily focusing on the CD40 receptor. This approach aims to enhance T cell priming and counteract the immunosuppressive nature of the tumor microenvironment, offering potential benefits for cancer patients across various cancer types. The company is headquartered in Lund, Sweden, and is listed on Nasdaq Stockholm under the ticker ATORX.
Average Trading Volume: 425,619
Technical Sentiment Signal: Sell
Current Market Cap: SEK161.9M
For a thorough assessment of ATORX stock, go to TipRanks’ Stock Analysis page.